Hydrangenol inhibits the proliferation, migration, and invasion of EJ bladder cancer cells via p21WAF1-mediated G1-phase cell cycle arrest, p38 MAPK activation, and reduction in Sp-1-induced MMP-9 expression

Authors

  • Seung-Shick Shin Department of Food Science and Nutrition, Jeju National University, Jeju 63243, South Korea
  • Myeong-Cheol Ko Department of ICT Convergence Engineering, College of Science and Technology, Konkuk University, Chungju, Chungbuk 27478, South Korea
  • Yu-Jin Park Department of Food and Nutrition, Chung-Ang University, Anseong, Kyung-gi 17546, South Korea
  • Byungdoo Hwang Department of Food and Nutrition, Chung-Ang University, Anseong, Kyung-gi 17546, South Korea
  • Sung Lyea Park Department of Food and Nutrition, Chung-Ang University, Anseong, Kyung-gi 17546, South Korea
  • Wun-Jae Kim Department of Urology, Chungbuk National University, Cheongju, Chungbuk 28644, South Korea
  • Sung-Kwon Moon Department of Food and Nutrition, Chung-Ang University, Anseong, Kyung-gi 17546, South Korea

DOI:

https://doi.org/10.17179/excli2018-1361

Keywords:

hydrangenol, proliferation, invasion, migration, MMP-9

Abstract

Hydrangenol is a dihydroisocoumarin that is mainly obtained from Hydrangea macrophylla. Recently, hydrangenol has garnered attention since several studies have reported that it has anti-inflammatory, anti-allergic, anti-diabetic, and anti-malarial activities. However, there have been few studies on the effect of hydrangenol on oncogenesis. In this study, we evaluated the anti-cancer activity of hydrangenol against the EJ bladder cancer cell line. Hydrangenol significantly inhibited the proliferation of EJ cells in a dose-dependent manner with an IC50 of 100 µM. Flow cytometry and immunoblotting experiments indicated that EJ cells were arrested in the G1-phase of the cell cycle and showed reduced expression of CDK2, CDK4, cyclin D1, and cyclin E mediated via the upregulation of p21WAF1. Hydrangenol increased the phosphorylation of p38 MAPK without affecting the phosphorylation of ERK and JNK. In addition, hydrangenol significantly inhibited the migratory and invasive activities of EJ cells by suppressing the enzymatic activity of MMP-9. Electrophoretic mobility shift assays suggested that the inhibition of MMP-9 activity by hydrangenol was attributable to its suppression of the Sp-1 transcription factor binding activity. This study is the first report on the mode of action of hydrangenol as an inhibitor of bladder cancer. We believe that these results provide novel insights that could aid the development of hydrangenol-based chemotherapeutic agents.

Downloads

Published

2018-06-06

How to Cite

Shin, S.-S., Ko, M.-C., Park, Y.-J., Hwang, B., Park, S. L., Kim, W.-J., & Moon, S.-K. (2018). Hydrangenol inhibits the proliferation, migration, and invasion of EJ bladder cancer cells via p21WAF1-mediated G1-phase cell cycle arrest, p38 MAPK activation, and reduction in Sp-1-induced MMP-9 expression. EXCLI Journal, 17, 531–543. https://doi.org/10.17179/excli2018-1361

Issue

Vol. 17 (2018)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).